View Older Stories View More Recent Stories

Aug 10, 2020 08:00AM Rubius Therapeutics Reports Second Quarter 2020 Financial Results and Positive Progress Across Pipeline
Aug 10, 2020 08:00AM Rubius Therapeutics Reports Second Quarter 2020 Financial Results and Positive Progress Across Pipeline
Aug 3, 2020 04:01PM Rubius Therapeutics to Announce Second Quarter 2020 Financial Results
Aug 3, 2020 04:01PM Rubius Therapeutics to Announce Second Quarter 2020 Financial Results
Jun 30, 2020 08:03AM Rubius Therapeutics (RUBY) Announces Update on Clinical Trial Progress for Lead Oncology Product Candidate RTX-240; CFO Andrew Oh to Depart Dec. 31, 2020
Jun 30, 2020 08:00AM Rubius Therapeutics Provides Update on Clinical Trial Progress for its Lead Oncology Product Candidate RTX-240 and Announces Planned Leadership Transition
Jun 30, 2020 08:00AM Rubius Therapeutics Provides Update on Clinical Trial Progress for its Lead Oncology Product Candidate RTX-240 and Announces Planned Leadership Transition
Jun 22, 2020 08:07AM Rubius Therapeutics (RUBY) Announces Preclinical Data for RTX-321 at AACR 2020 Virtual Meetings
Jun 22, 2020 08:00AM Rubius Therapeutics Highlights Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers, at the American Association of Cancer Research Virtual Annua
Jun 22, 2020 08:00AM Rubius Therapeutics Highlights Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers, at the American Association of Cancer Research Virtual Annua
May 26, 2020 04:01PM Rubius Therapeutics to Present at Jefferies Virtual 2020 Healthcare Conference
May 26, 2020 04:01PM Rubius Therapeutics to Present at Jefferies Virtual 2020 Healthcare Conference
May 15, 2020 08:00AM Rubius Therapeutics to Present Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers at the American Association of Cancer Research Annual Meeting
May 15, 2020 08:00AM Rubius Therapeutics to Present Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers at the American Association of Cancer Research Annual Meeting
May 12, 2020 06:00AM Rubius Therapeutics Highlights Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers, at the American Society of Gene & Cell Therapy 23rd Annual M
May 12, 2020 06:00AM Rubius Therapeutics Highlights Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers, at the American Society of Gene & Cell Therapy 23rd Annu
May 11, 2020 08:00AM Rubius Therapeutics Reports First Quarter 2020 Financial Results and Provides Operational Update
May 11, 2020 08:00AM Rubius Therapeutics Reports First Quarter 2020 Financial Results and Provides Operational Update
May 7, 2020 08:14AM Rubius Therapeutics (RUBY) Reports First Patient Dosing in Phase 1/2 Trial of RTX-240
May 7, 2020 08:00AM Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-240, an Allogeneic Cellular Therapy, for the Treatment of Solid Tumors
May 7, 2020 08:00AM Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-240, an Allogeneic Cellular Therapy, for the Treatment of Solid Tumors
May 4, 2020 04:01PM Rubius Therapeutics to Announce First Quarter 2020 Financial Results
May 4, 2020 04:01PM Rubius Therapeutics to Announce First Quarter 2020 Financial Results
Apr 29, 2020 08:00AM Rubius Therapeutics Announces Preclinical Data from Red Cell Therapeutic Oncology Programs to be Presented at the ASGCT 23rd Annual Meeting
Apr 29, 2020 08:00AM Rubius Therapeutics Announces Preclinical Data from Red Cell Therapeutic Oncology Programs to be Presented at the ASGCT 23rd Annual Meeting
Mar 12, 2020 07:00AM Rubius Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Announces Strategic Focus on Oncology and Autoimmunity
Mar 12, 2020 07:00AM Rubius Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Announces Strategic Focus on Oncology and Autoimmunity
Mar 3, 2020 04:01PM Rubius Therapeutics to Report Fourth Quarter and Full-Year 2019 Financial Results and Host Webcast
Mar 3, 2020 04:01PM Rubius Therapeutics to Report Fourth Quarter and Full-Year 2019 Financial Results and Host Webcast
Jan 30, 2020 08:00AM Rubius Therapeutics Announces First Patient Dosed in Phase 1b Trial of RTX-134 for the Treatment of Patients with Phenylketonuria
Jan 30, 2020 08:00AM Rubius Therapeutics Announces First Patient Dosed in Phase 1b Trial of RTX-134 for the Treatment of Patients with Phenylketonuria
Jan 13, 2020 08:18AM Rubius Therapeutics (RUBY) Announces 2020 Objectives and Provides Operational Update
Jan 13, 2020 08:00AM Rubius Therapeutics Announces 2020 Objectives and Provides Operational Update at the 38th Annual J.P. Morgan Healthcare Conference
Jan 13, 2020 08:00AM Rubius Therapeutics Announces 2020 Objectives and Provides Operational Update at the 38th Annual J.P. Morgan Healthcare Conference
Jan 8, 2020 08:00AM Rubius Therapeutics Appoints Internationally Recognized Autoimmunity and Translational Immunology Leader Laurence Turka, M.D., as Chief Scientific Officer
Jan 8, 2020 08:00AM Rubius Therapeutics Appoints Internationally Recognized Autoimmunity and Translational Immunology Leader Laurence Turka, M.D., as Chief Scientific Officer
Jan 2, 2020 04:05PM Rubius Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
Jan 2, 2020 04:05PM Rubius Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
Dec 23, 2019 08:07AM Rubius Therapeutics (RUBY) Appoints Christina Coughlin, M.D., Ph.D., as CMO
Dec 23, 2019 08:00AM Rubius Therapeutics Appoints Christina Coughlin, M.D., Ph.D., as Chief Medical Officer
Dec 23, 2019 08:00AM Rubius Therapeutics Appoints Christina Coughlin, M.D., Ph.D., as Chief Medical Officer
Dec 18, 2019 08:09AM Rubius Therapeutics (RUBY) Names Anne Prener, M.D., Ph.D., to its Board
Dec 18, 2019 08:05AM Rubius Therapeutics Appoints Anne Prener, M.D., Ph.D., to its Board of Directors
Dec 18, 2019 08:05AM Rubius Therapeutics Appoints Anne Prener, M.D., Ph.D., to its Board of Directors
Nov 14, 2019 08:00AM Rubius Therapeutics Reports Third Quarter 2019 Financial Results and Operational Progress
Nov 14, 2019 08:00AM Rubius Therapeutics Reports Third Quarter 2019 Financial Results and Operational Progress
Nov 12, 2019 04:05PM Rubius Therapeutics to Participate in Jefferies London Healthcare Conference
Nov 12, 2019 04:05PM Rubius Therapeutics to Participate in Jefferies London Healthcare Conference
Nov 12, 2019 08:00AM Rubius Therapeutics Appoints Maiken Keson-Brookes as Chief Legal Officer and Corporate Secretary
Nov 12, 2019 08:00AM Rubius Therapeutics Appoints Maiken Keson-Brookes as Chief Legal Officer and Corporate Secretary
View More Recent Stories View Older Stories